News, Short Squeeze, Breakout and More Instantly...
REGENXBIO Announces Presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference PR Newswire ROCKVILLE, Md. , Aug. 10, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the H.C. Wainwright 2...
REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights PR Newswire RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, remains on track for first BLA filing in 2024 ...
REGENXBIO Announces Intention to File a Biologics License Application Using the Accelerated Approval Pathway for RGX-121, an AAV Therapeutic for the Treatment of MPS II PR Newswire FDA will consider an accelerated approval pathway for RGX-121; BLA filing expected in ...